EUVIMEDEUVIMED entdecken
Crossref

Aztreonam-amoxicillin/clavulanate combination therapy against bla NDM-producing Enterobacterales infections

Efrat Orenbuch-Harroch, Gabriella Snoyman, Munther Aqeel Nashashibi, Violeta Temper, Yonatan Oster iD, Daniel Grupel iD, Dan Reshef, Jacob Moran-Gilad, Jacob Strahilevitz iD

Journal of Antimicrobial Chemotherapy · 2025

DOI: 10.1093/jac/dkaf379 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Antimicrobial Chemotherapy, 2025. Verfasst von Efrat Orenbuch-Harroch und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical Microbiology and Infectious Diseases, Hadassah Hebrew University Medical Center, Jerusalem, Israel. Hauptthemen laut MEDLINE: Aztreonam, Enterobacteriaceae Infections, Anti-Bacterial Agents, beta-Lactamases. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 24 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Aztreonam plus ceftazidime/avibactam is recommended against NDM-producing Enterobacterales. Pairing with clavulanate can also restore aztreonam’s activity.

Objectives

To report on the clinical experience with antimicrobial susceptibility testing–guided aztreonam therapy combined with β-lactamase inhibitors, particularly amoxicillin-clavulanate, against NDM-producing Enterobacterales infections.

Methods

All patients with infections caused by NDM-producing Enterobacterales that were resistant to aztreonam monotherapy but demonstrated in vitro synergy and thus eligible for aztreonam combination therapy, who received ≥5 days of aztreonam-based combination therapy, were included. Gradient strip-crossing methodology was validated against broth microdilution for susceptibility testing. Clinical response was assessed at 30 days post-treatment.

Results

Clinical cure was achieved in 78% (7/9) of aztreonam/amoxicillin-clavulanate patients and 56% (9/16) of aztreonam/ceftazidime-avibactam patients. Treatment duration averaged 11.8 and 11.6 days, respectively. Among 21 sequenced isolates, blaNDM-1 was most prevalent. In vitro synergy was demonstrated in 52% with clavulanate and 90% of isolates with avibactam. Gradient strip-crossing showed 80% essential agreement and 100% categorical agreement for both combinations. Transient hepatic enzyme elevations occurred in three liver transplant recipients.

Conclusions

Our findings suggest aztreonam/amoxicillin-clavulanate combination therapy guided by gradient strip-crossing as a potential broad-spectrum-sparing strategy for selected patients with NDM-producing Enterobacterales infections.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

AztreonamEnterobacteriaceae InfectionsAnti-Bacterial Agentsbeta-Lactamasesbeta-Lactamase InhibitorsAmoxicillin-Potassium Clavulanate CombinationEnterobacteriaceaeHumansMaleMicrobial Sensitivity TestsFemaleMiddle AgedDrug Therapy, CombinationAgedTreatment OutcomeAdultAged, 80 and over

Substanzen

AztreonamAnti-Bacterial Agentsbeta-Lactamasesbeta-Lactamase InhibitorsAmoxicillin-Potassium Clavulanate Combinationbeta-lactamase NDM-1

Autor:innen und Institutionen

  • Department of Clinical Microbiology and Infectious Diseases, Hadassah Hebrew University Medical Center, Jerusalem, Israel.
  • Department of Medicine, Hadassah Hebrew University Medical Center, Jerusalem, Israel.
  • Faculty of Medicine, Hebrew University, Jerusalem, Israel.

ORCID-Profile: Yonatan Oster, Daniel Grupel, Jacob Strahilevitz

Zitieren

APA

Orenbuch-Harroch, E., Snoyman, G., Nashashibi, M. A., Temper, V., Oster, Y., Grupel, D., Reshef, D., Moran-Gilad, J., & Strahilevitz, J. (2025). Aztreonam-amoxicillin/clavulanate combination therapy against bla NDM-producing Enterobacterales infections. Journal of Antimicrobial Chemotherapy. https://doi.org/10.1093/jac/dkaf379

Vancouver

Orenbuch-Harroch E, Snoyman G, Nashashibi MA, Temper V, Oster Y, Grupel D, et al. Aztreonam-amoxicillin/clavulanate combination therapy against bla NDM-producing Enterobacterales infections. Journal of Antimicrobial Chemotherapy. 2025. doi:10.1093/jac/dkaf379

BibTeX
@article{OrenbuchHarroch2025,
  author = {Orenbuch-Harroch, Efrat and Snoyman, Gabriella and Nashashibi, Munther Aqeel and Temper, Violeta and Oster, Yonatan and Grupel, Daniel and Reshef, Dan and Moran-Gilad, Jacob and Strahilevitz, Jacob},
  title = {Aztreonam-amoxicillin/clavulanate combination therapy against bla NDM-producing Enterobacterales infections},
  journal = {Journal of Antimicrobial Chemotherapy},
  year = {2025},
  doi = {10.1093/jac/dkaf379}
}
Kostenlos starten →